We remind investors that in Jul 2013, Insmed reported encouraging results from a phase III study on Arikace for the treatment of Pa in CF patients, when compared to twice-daily Novartis’ (NVS) TOBI (tobramycin inhalation solution). Insmed plans to submit marketing applications for Arikace in the EU and Canada by mid-2014.
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
• ACE Limited (ACE)
• Activision Blizzard, Inc. (ATVI)
• American Capital Agency Corp. ( AGNC)
• Astronics Corporation ( ATRO )
• Athlon Energy Inc (ATHL)
Right... NWBO in Phase III, but a article today, http://www.forbes.com/sites/tommeyer/2013/12/27/the-race-to-develop-a-brain-cancer-treatment-takes-an-interesting-turn/?partner=yahootix, equated NWBO;'s failure with ImmunoCellular Therapeutics (NYSEMKT:IMUC), But IMUC failed in Phase II.
What are they talking about??????